MacroGenics, Inc. (NASDAQ:MGNX) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET

Company Participants

Jim Karrels - SVP and CFO

Dr. Scott Koenig - President and CEO

Conference Call Participants

Jessica Hui - Evercore

Jonathan Chang - SVB Securities

David Dai - SMBC

Charles Zhu - Guggenheim Partners

Silvan Tuerkcan - JMP Securities

Operator

Good afternoon. We will begin the MacroGenics 2022 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructions]

At this point, I will turn the call over to Jim Karrels, Senior Vice President, Chief Financial Officer of MacroGenics.

Jim Karrels

Thank you, operator. Good afternoon, and welcome to MacroGenics Conference Call to discuss our third quarter 2022 financial and operational results. For anyone who's not had the chance to review these results, we issued a press release this afternoon outlining today's announcements, which is available under the Investors tab on our website at macrogenics.com.

You may also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately 2 hours after the call is completed.

I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual, quarterly and current reports filed with the SEC.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change, except to the extent required by applicable law.

And now I would like to turn the call over to Dr. Scott Koenig, President and CEO of MacroGenics.

Dr. Scott Koenig

Thank you, Jim. I'd like to welcome everyone participating via conference call and webcast today. This afternoon, I will provide key updates on our clinical programs as well as our recently announced collaboration with Gilead.

But before I do so, let me first turn the call back to Jim, who will review our financial results.